Methadone switching for refractory cancer pain

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Refractory cancer pain poses a significant challenge in palliative care.
• Methadone is explored as an alternative opioid treatment for such cases.
• Evaluating methadone's efficacy, safety, and cost is crucial for optimizing cancer pain management.

Purpose of the Study:

• To investigate the efficacy of methadone in treating refractory cancer pain.
• To assess the safety and adverse event profile of methadone compared to prior opioid regimens.
• To determine the cost-effectiveness of using methadone for cancer pain.

Main Methods:

• Retrospective study of 90 patients with refractory cancer pain from April 2016 to December 2020.
• Comparison of pain control (pain score, breakthrough pain frequency) and adverse events before and after methadone initiation.
• Multivariate analysis of factors influencing switching outcomes and estimation of pain control costs.

Main Results:

• Successful switching to methadone in 71.1% of patients, with significant reductions in pain scores and breakthrough pain frequency.
• Similar adverse event profiles (constipation, nausea, vomiting, dizziness) between methadone and prior opioids.
• Median daily analgesic cost reduced from $19.5 to $10.8 post-methadone switch; the 3-day switch method improved success rates.

Conclusions:

• Methadone is an effective and safe treatment option for refractory cancer pain.
• Switching to methadone leads to significant pain reduction and improved quality of life.
• Methadone provides a cost-saving benefit for managing refractory cancer pain.